

December 16, 2015

---

# NEMUS Announces In-Licensing of Cannabidiol (CBD) Derivatives From the University of Mississippi

COSTA MESA, CA -- (Marketwired) -- 12/16/15 -- NEMUS Bioscience, Inc. (OTCQB: NMUS) has announced the in-licensing of derivative formulations of the cannabinoid molecule, cannabidiol (CBD). CBD is differentiated from tetrahydrocannabidiol (THC) in that it is a non-psychoactive cannabinoid with multiple associated activities in mammalian systems, including but not limited to, immune regulation, anti-inflammatory and anti-cancer activity, neuro-modulation and neuroprotective qualities. The in-licensing includes not only formulation derivatives of the CBD molecule but also multiple routes of administration and methods of use.

"Having CBD in our product portfolio allows NEMUS to pursue new indications while also enhancing our ophthalmology program," commented Brian Murphy, MD, MPH, who serves as CEO and CMO of NEMUS. "CBD complements our ocular THC prodrug, establishing a potential ophthalmology franchise for NEMUS, especially in leveraging the neuroprotective qualities of the CBD molecule. In addition to glaucoma, other possible ophthalmic disorders to be addressed could be certain forms of retinopathy and macular degeneration."

"For forty-seven years, the University of Mississippi has established a globally recognized expertise in the chemistry and physiology of cannabinoid molecules," stated Dr. Mahmoud ElSohly, professor at the National Center for Natural Products Research at the university. "We look forward to developing these and other cannabinoid derivatives in the pursuit of new medicines to alleviate the burden of disease with our research partner, NEMUS Bioscience."

"The neuromodulatory and protective qualities of CBD will allow NEMUS to explore new therapeutic areas such as neuropathic pain and anti-infective opportunities such as methicillin-resistant staphylococcus aureus (MRSA)," reports Dr. Murphy.

"The molecular engineering involved in these compounds enhances the transposition of the derivatives across membranes that is superior to using the parent cannabinoid molecules," stated Dr. Soumyajit Majumdar, Associate Professor of Pharmaceutics and Drug Delivery and Associate Dean for Research in the School of Pharmacy at the university. "In ocular approaches, this can result in delivery to the posterior chamber of the eye and the retinal ganglion cells implicated in multiple disease processes."

"NEMUS looks forward to presenting data on these programs in 2016 and to advance both ophthalmic and systemic formulations of unique THC and CBD compounds," stated Dr. Murphy.

## ***ABOUT NEMUS BIOSCIENCE, INC.***

The Company is a biopharmaceutical company, headquartered in Costa Mesa, California,

focused on the discovery, development, and commercialization of cannabis-based therapeutics for significant unmet medical needs in global markets. Utilizing certain proprietary technology licensed from the University of Mississippi, NEMUS is working to develop novel ways to deliver cannabis-based drugs for specific indications, with the aim of optimizing the clinical effects of such drugs, while limiting the potential adverse events. NEMUS's strategy will explore the use of natural and synthetic compounds, alone or in combination. The Company is led by a highly qualified team of executives with decades of biopharmaceutical experience and significant background in early-stage drug development. For more information, visit [www.NEMUSbioscience.com](http://www.NEMUSbioscience.com).

## **FORWARD LOOKING STATEMENTS**

Statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties, including statements about the potential benefits and developments that may be achieved under the license arrangement and NEMUS' consideration of strategic business relationships. In some cases, forward-looking statements can be identified by terminology including "goal," "focus," "aims," "believes," "can," "challenge," "predictable" "will," or the negative of these terms or other comparable terminology. We operate in a rapidly-changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, uncertainty regarding the ability to achieve the expected benefits from the proposed license agreement and other risks that are described in the Risk Factors section of NEMUS' most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, NEMUS disclaims any intent or obligation to update these forward-looking statements.

Investor Relations

Mike Cole

Vice President -- MZ North America

Main: 949-259-4988

Mobile: 949-444-1341

[mike.cole@mzgroup.us](mailto:mike.cole@mzgroup.us)

[www.mzgroup.us](http://www.mzgroup.us)

Source: Nemus Bioscience